A Phase 3 interventional study of BMS-986165 in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 27 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-11-02.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.
Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 14th largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 3, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in Argentina, Australia, Brazil and 10 more countries
Ages 4–18
Bristol-Myers Squibb
Ages 4–75
By country, each count listing its studies:
deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 10 · Phase 4 8
First in 2016; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is close to the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 102 across the 26 interventional studies. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Psoriasis by Bristol-Myers Squibb: 9 open now, 14 under way, 4 of them phase 3. Of 28 finished, 10 (36%) have results posted.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 19th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2019, is one of 9 in phase 3, and was the 17th registered.
Bristol-Myers Squibb’s Psoriasis studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing deucravacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 42 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
a. For participants with plaque psoriasis: i. Stable plaque psoriasis for at least 6 months ii. Moderate to severe disease iii. Candidate for phototherapy or systemic therapy b. Additional protocol-specified inclusion criteria apply for subjects with psoriatic arthritis, erythrodermic psoriasis, or generalized pustular psoriasis
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Given daily
Drug: BMS-986165
Oral tablet administration
Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16
The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as clear (0) or almost clear (1) with at least 2-point improvement from baseline at week 16 using the non-responder imputation (NRI) method. The higher sPGA score denotes to more severe disease activity: * Clear (0) * Almost clear (1) * Mild (2) * Moderate (3) * Severe (4)
Time frame: Week 16
Psoriasis Area and Severity Index (PASI) 75 Response Assessed as a Number of Participants Who Achieve a 75% Improvement From Baseline in the PASI Score at Week 16
PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method.
Time frame: Week 16
| Milestone | Deucravacitinib 6 mg QD |
|---|---|
| Started | 74 |
| Completed | 68 |
| Not completed | 6 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 1 |
The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as clear (0) or almost clear (1) with at least 2-point improvement from baseline at week 16 using the non-responder imputation (NRI) method. The higher sPGA score denotes to more severe disease activity: * Clear (0) * Almost clear (1) * Mild (2) * Moderate (3) * Severe (4)
| Participants | Plaque Psoriasis 6 mg QD | Generalized Pustular Psoriasis 6 mg QD | Erythrodemic Psoriasis 6 mg QD |
|---|---|---|---|
| Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16 | 52 | 0 | 4 |
PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method.
| Participants | Plaque Psoriasis 6 mg QD | Generalized Pustular Psoriasis 6 mg QD | Erythrodemic Psoriasis 6 mg QD |
|---|---|---|---|
| Psoriasis Area and Severity Index (PASI) 75 Response Assessed as a Number of Participants Who Achieve a 75% Improvement From Baseline in the PASI Score at Week 16 | 48 | 2 | 3 |
Collected over Serious Adverse Events and Adverse Events were monitored from first dose to 30 days post last dose (Up to approximately 3 months). Participants were assessed for All Cause Mortality from their date of randomization until study completion (Up to approximately 23 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Deucravacitinib 6 mg QD | 0/74 (0%) | 5/74 (6.8%) | 40/74 (54.1%) |
| Event | Deucravacitinib 6 mg QD |
|---|---|
| COVID-19Infections and infestations | 1/74 |
| PneumoniaInfections and infestations | 1/74 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/74 |
| Normal pressure hydrocephalusNervous system disorders | 1/74 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/74 |
| Event | Deucravacitinib 6 mg QD |
|---|---|
| NasopharyngitisInfections and infestations | 23/74 |
| AcneSkin and subcutaneous tissue disorders | 7/74 |
| ConstipationGastrointestinal disorders | 4/74 |
| StomatitisGastrointestinal disorders | 4/74 |
| PeriodontitisInfections and infestations | 4/74 |
| Upper respiratory tract infectionInfections and infestations | 4/74 |
| PsoriasisSkin and subcutaneous tissue disorders | 4/74 |
| Age, Continuous(Years) | Deucravacitinib 6 mg QD |
|---|---|
| Mean | 48.6 ± 11.72 |
| Sex: Female, Male(Participants) | Deucravacitinib 6 mg QD |
|---|---|
| Female | 17 |
| Male | 57 |
| Race/Ethnicity, Customized(Participants) | Deucravacitinib 6 mg QD |
|---|---|
| Asian - Japanese | 73 |
| Asian - Non-Japanese | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Mar 2021, 23 months.
Results were first posted in Nov 2022, 1 year 7 months after primary completion. A results delay was requested in Mar 2022.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib